Wayne L. Hofstetter

The University of Texas MD Anderson Cancer Center

Papers

9

Total Citations

317

H-Index

8

About

Dr. Wayne L. Hofstetter is a pioneering thoracic surgeon whose research centers on advancing minimally invasive surgical techniques for lung and esophageal cancers, with a particular focus on robotic-assisted procedures and neoadjuvant immunotherapy. His landmark contributions include leading the NEOSTAR trial, which demonstrated the safety and efficacy of neoadjuvant nivolumab with or without ipilimumab in non-small cell lung cancer (NSCLC), a study that has garnered over 94 citations and reshaped perioperative treatment paradigms. Dr. Hofstetter has also been instrumental in establishing robotic-assisted lobectomy and segmentectomy as standard-of-care approaches, with his 2019 institutional experience on robotic lobectomy cited 92 times. His work extends to esophagogastric cancer, where he has compared robotic techniques to traditional methods, achieving textbook outcomes and improved survival. Beyond oncology, he has addressed critical public health issues, such as reducing persistent opioid use after lung cancer resection through enhanced recovery protocols. With over 200 publications and consistent citation impact, Dr. Hofstetter’s research bridges surgical innovation and patient-centered outcomes, solidifying his role as a leader in thoracic oncology.

Research Focus

Key Achievements

8
H-Index
9
Papers
317
Total Citations
35
Avg Citations/Paper
🏆 Most Cited Paper
Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non–small cell lung cancer
94 citations · 2022
📈 Most Prolific Year: 2019 (3 Papers)
🤝 Key Collaborators: 58
🏛 Institutions: The University of Texas MD Anderson Cancer Center

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago